BioMarin Pharmaceutical Inc. (BMRN) — Stock Score Summary

BioMarin Pharmaceutical Inc. (BMRN) has a MoatMap StockRank of 84/100 based on Quality (65/100), Value (39/100), and Momentum (65/100) factor scores. The current signal is STRONG BUY. BioMarin is a biotech firm focused on rare diseases. While it has high-margin products, it is not a CDMO and does not benefit from the CDMO pricing power cycle; it is a drug developer subject to binary clinical and regulatory risks.

BioMarin Pharmaceutical Inc. is a global biotechnology company dedicated to developing and commercializing innovative therapies for rare genetic diseases, including treatments for PKU and achondroplasia. The company's competitive moat arises from its specialized focus on ultra-orphan indications, which entail high barriers to entry due to complex research and regulatory pathways, alongside deep engagement with patient communities. BioMarin is a prominent player in rare disease biopharmaceuticals, delivering critical treatments to underserved populations.

Key Financial Metrics

Price$57.91
Market Cap$10.2B
P/E (TTM)40.63
P/E (Forward)8.74
Price/Book1.76
Return on Equity4.5%
Return on Invested Capital7.2%
Debt/Equity23.17
Gross Margin51.2%
Operating Margin18.0%
Revenue Growth2.8%
Free Cash Flow$459M

BioMarin Pharmaceutical Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BioMarin Pharmaceutical Inc.’s (BMRN) StockRank?
MoatMap’s StockRank for BioMarin Pharmaceutical Inc. (BMRN) is 84/100, with a Strong Buy signal. It is a composite of Quality (65), Value (39), and Momentum (65) factor ranks across MoatMap’s 19,000+ stock universe.
Does BioMarin Pharmaceutical Inc. have an economic moat?
BioMarin Pharmaceutical Inc. (BMRN) has a Quality factor score of 65/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BioMarin Pharmaceutical Inc. a buy, hold, or sell?
MoatMap’s current signal for BioMarin Pharmaceutical Inc. (BMRN) is Strong Buy, based on a StockRank of 84/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BioMarin Pharmaceutical Inc. in?
BioMarin Pharmaceutical Inc. (BMRN) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksBMRN deep dive reportAI ChampionsHow we score stocksSense-check another stock